Journal Article

Early tolerance and late persistence as alternative drug responses in cancer

Cittaro, Davide, Battistini, Chiara, Villanti, Ilaria, Punzi, Simona, Crupi, Gemma, Cartalemi, Antonino Alex, Cavallaro, Ugo, Palumbo, Martina, Antoniotti, Marco, Botrugno, Oronza A., Lanfrancone, Luisa, Giansanti, Valentina, Nagel, Zachary, Giannese, Francesca, Oneto, Caterina, Gutfreund, Alon, Graudenzi, Alex, Patruno, Lucrezia, Tonon, Giovanni, Laverty, Daniel J., Caravagna, Giulio, Balaban, Nathalie, Gatti, Guido, Santacatterina, Giovanni, Draetta, Giulio, Yap, Timothy A.

2025

Overview

Bacteria withstand antibiotic treatment through three alternative mechanisms: resistance, persistence or tolerance. While resistance and persistence have been described, whether drug-induced tolerance exists in cancer cells remains largely unknown. Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. After prolonged drug exposure, such tolerant responses morph into persistence, whereby the increased DNA damage repair is entirely reversed. The central regulator of mitophagy PINK1 drives this reduction in DNA repair via the cytoplasmic relocalization of the cell identity master HNF4A , thus hampering HNF4A transcriptional activation of DNA repair genes. We conclude that exposing cancer cells to relevant standard-of-care antitumour therapies induces a pervasive drug-induced tolerant response that might be broadly exploited to increase the impact of first-line, adjuvant treatments and debulking in advanced cancers. Bacteria are able to withstand antibiotic treatment through three mechanisms, resistance, persistence or tolerance. Here, the authors investigate whether such mechanisms as defined in bacteria also apply to human cancer cells, finding that exposure to chemotherapy elicits an atavistic tolerant response in human cancer cells, providing key survival advantages.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 13/2 / 13/31 / 13/95 / 14/33 / 45/91 / 59/5 / 631/67/1059 / 631/67/1059/2326 / 631/67/69 / 64/60 / 96/44 / Antibiotics / Antineoplastic Agents - pharmacology / Antitumor activity / Autophagy / Autophagy - drug effects / Bacteria / Cancer / Cancer therapies / Cell activation / Cell Line, Tumor / Cell survival / Chemotherapy / Damage tolerance / Deoxyribonucleic acid / DNA / DNA damage / DNA Damage - drug effects / DNA repair / DNA Repair - drug effects / DNA Repair - genetics / Drug Resistance, Neoplasm - genetics / Drug Tolerance / Exposure / Hepatocyte nuclear factor 4 / Hepatocyte Nuclear Factor 4 - genetics / Hepatocyte Nuclear Factor 4 - metabolism / Humanities and Social Sciences / Humans / Mitophagy / Mitophagy - drug effects / multidisciplinary / Neoplasms - drug therapy / Neoplasms - genetics / Neoplasms - pathology / Protein Kinases - genetics / Protein Kinases - metabolism / PTEN-induced putative kinase / Science / Science (multidisciplinary) / Transcription activation